StockNews.com Begins Coverage on Brainstorm Cell Therapeutics (NASDAQ:BCLI)

Equities research analysts at StockNews.com initiated coverage on shares of Brainstorm Cell Therapeutics (NASDAQ:BCLIGet Free Report) in a research note issued to investors on Tuesday. The brokerage set a “hold” rating on the biotechnology company’s stock.

Brainstorm Cell Therapeutics Trading Up 5.3 %

Shares of Brainstorm Cell Therapeutics stock opened at $0.43 on Tuesday. The firm has a market cap of $30.35 million, a PE ratio of -1.35 and a beta of 0.43. The stock has a 50 day moving average of $0.53 and a 200 day moving average of $0.40. Brainstorm Cell Therapeutics has a 12 month low of $0.13 and a 12 month high of $2.91.

Brainstorm Cell Therapeutics (NASDAQ:BCLIGet Free Report) last posted its earnings results on Tuesday, May 14th. The biotechnology company reported ($0.05) EPS for the quarter, beating analysts’ consensus estimates of ($0.07) by $0.02. As a group, equities research analysts forecast that Brainstorm Cell Therapeutics will post -0.28 earnings per share for the current fiscal year.

Institutional Trading of Brainstorm Cell Therapeutics

A hedge fund recently bought a new stake in Brainstorm Cell Therapeutics stock. Kingswood Wealth Advisors LLC bought a new stake in shares of Brainstorm Cell Therapeutics Inc. (NASDAQ:BCLIFree Report) during the 1st quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund bought 81,050 shares of the biotechnology company’s stock, valued at approximately $46,000. Kingswood Wealth Advisors LLC owned about 0.12% of Brainstorm Cell Therapeutics as of its most recent filing with the Securities and Exchange Commission. Hedge funds and other institutional investors own 14.33% of the company’s stock.

Brainstorm Cell Therapeutics Company Profile

(Get Free Report)

Brainstorm Cell Therapeutics Inc, a biotechnology company, engages in the development and commercialization of autologous cellular therapies for the treatment of neurodegenerative diseases. The company, through its NurOwn proprietary cell therapy platform, leverages cell culture methods to induce autologous bone marrow-derived mesenchymal stem cells to secrete high levels of neurotrophic factors, modulate neuroinflammatory and neurodegenerative disease processes, promote neuronal survival, and enhance neurological function.

Further Reading

Receive News & Ratings for Brainstorm Cell Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Brainstorm Cell Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.